title: Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.
authors.affiliation: Department of Medical Oncology, II, National Institute for Cancer Research, Genoa, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Decensi
authors.forename: S
authors.initials: S
authors.lastname: Bruno
authors.forename: M
authors.initials: M
authors.lastname: Costantini
authors.forename: R
authors.initials: R
authors.lastname: Torrisi
authors.forename: A
authors.initials: A
authors.lastname: Curotto
authors.forename: B
authors.initials: B
authors.lastname: Gatteschi
authors.forename: G
authors.initials: G
authors.lastname: Nicolò
authors.forename: A
authors.initials: A
authors.lastname: Polizzi
authors.forename: M
authors.initials: M
authors.lastname: Perloff
authors.forename: W F
authors.initials: WF
authors.lastname: Malone
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004273:DNA, Neoplasm / Q000032:analysis*; D003623:Dark Adaptation / Q000187:drug effects; D005240:Feasibility Studies; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D004273:DNA, Neoplasm; D017313:Fenretinide